| Trial Acronym | EViSCO |
| Clinical Area | Respiratory |
| Description | Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease |
| Status | Analysis and Reporting |
| Target Recruitment | 88 |
| Recruitment to date | 85 as of 31/03/2020 (recruitment closed) |
| Trial Design | Randomised double-blind, placebo-controlled trial of 1 gram three times daily of valaciclovir or placebo for 8 weeks in COPD patients with Epstein-Barr virus |
| Study Aim | To establish if an antiviral therapy (valaciclovir) used to treat other herpes viruses is safe in patients with COPD and to examine whether it is possible to supress EBV in the airways of patients with COPD and examine important outcome measures including lung function and markers of airway inflammation in the blood and sputum. |
| Chief Investigator | Dr Joe Kidney |
| Sponsors | Belfast Health and Social Care Trust |
| Funder | Mater YP Trustees |